Kelli Boyd

Jacek Hawiger, MD, PhD, third from right, with study team members, from left, Katherine Gibson-Corley, DVM, PhD, Yan Liu, MD, Jozef Zienkiewicz, PhD, Huan Qiao, MD, PhD, and Ruth Ann Veach.
November 10, 2022

Hawiger still blazing a trail in inflammation research

Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

By Bill Snyder